Nanobiotechnology for Hemoglobin-based Blood Substitutes

Critical Care Clinics

Volumn 25, Issue 2, 2009, Pages 373-382

  Chang, T M S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Blood substitutes; Catalase; Fibrinogen; Hemoglobin; Melanoma; Nanobiotechnology; Nanomedicine; Polyhemoglobin; Superoxide dismutase; Tyrosinase

Indexed keywords

ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; CATALASE; FIBRINOGEN; HEMOGLOBIN; MONOPHENOL MONOOXYGENASE; SUPEROXIDE DISMUTASE;

BIODEGRADABILITY; BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; DRUG FORMULARY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; NANOBIOTECHNOLOGY; NANOMEDICINE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN AFFINITY; OXYGEN TRANSPORT; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION;

ANIMALS; BLOOD SUBSTITUTES; CATTLE; HEMOGLOBINS; HUMANS; NANOTECHNOLOGY; OXYGEN;

EID: 62249125328     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2008.12.006     Document Type: Review

References (31)

1. Chang T.M.S. Semipermeable microcapsules. Science 146 3643 (1964) 523-525
2. Chang T.M.S. Artificial cells. Monograph (1972), Springfield (IL), Charles C Thomas. http://www.artcell.mcgill.ca Accessed February 17, 2009
3. Chang T.M.S. Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. Biochem Biophys Res Commun 44 6 (1971) 1531-1536
4. Chang T.M.S. Artificial cells: biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy (2007), Singapore: World Science Publisher p. 452
5. Chang T.M.S. Blood substitutes: principles, methods, products and clinical trials Vol 1 (1997), Karger, Basel, Switzerland. http://www.artcell.mcgill.ca Accessed February 17, 2009
6. Chang T.M.S. Nanobiotechnological modification of hemoglobin and enzymes from this laboratory. Biochim Biophys Acta 1784 (2008) 1435-1440
7. Chang T.M.S. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Singapore: World Science Publisher; (2007) p. 31-61
8. Perutz, MF. Stereochemical mechanism of oxygen transport by hemoglobin. Proc R Soc Lond B 1980;208:135.
9. Gould S.A., Moore E.E., Hoyt D.B., et al. The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J Am Coll Surg 195 (2002) 445-452
10. Pearce L.B., Gawryl M.S., Rentko V.T., et al. HBOC-201 (Hb Glutamer-250 (Bovine), Hemopure): clinical studies. In: Winslow R. (Ed). Blood substitutes (2006), Academic Press, San Diego 437-450
11. Moore E.E., Moore F.A., Fabian T.C., et al. Human polymerized hemoglobin for the treatment of hermorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 208 (2009) 1-13
12. Yu B.L., Liu Z.C., Chang T.M.S., et al. PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artif Cells Blood Substit Immobil Biotechnol 34 (2006) 159-175
13. D'Agnillo F., and Chang T.M.S. PolyHb-superoxide dismutase catalase as a blood substitute with antioxidant properties. Nat Biotechnol 16 7 (1998) 667-671
14. Chang TMS, F. D'Agnillo, S. Razack, A second generation Hb based blood substitute with antioxidant activities. In: Blood substitutes: principles, methods, products and clinical trials, vol. 2. Chang, TMS, edition. Basel Karger Texas Landes, 1998;1009:175-85.
15. Powanda D., and Chang T.M.S. Cross-linked polyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artif Cells Blood Substit Immobil Biotechnol 30 (2002) 25-42
16. Chang T.M.S. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions. Chang TMS, editor. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Singapore: World Science Publisher; 2007 (2007) 62-92
17. Wong N., and Chang T.M.S. Polyhemoglobin-fibrinogen: a novel blood substitute with platelet-like activity for extreme hemodilution. Artif Cells Blood Substit Immobil Biotechnol 35 (2007) 481-489
18. Chang T.M.S. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng 1 (1976) 25-32
19. Chang T.M.S. Nanotechnology based artificial red blood cells. Chang TMS, editor. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Singapore: World Science Publisher; 2007 (2007) 93-128
20. Yu W.P., and Chang T.M.S. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes: a preliminary report. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 889-894
21. Yu W.P., and Chang T.M.S. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 24 (1996) 169-184
22. Chang T.M.S., and Yu W.P. Nanoencapsulation of Hb and RBC enzymes based on nanotechnology and biodegradable polymer. In: Chang T.M.S. (Ed). Blood substitutes: principles, methods, products and clinical trials Vol. 2 (1998), Karger, Basel 216-231
23. Chang T.M.S. Artificial cells with cofactor regenerating multienzyme systems. Methods Enzymol 112 (1985) 195-203
24. Chang T.M.S., Powanda D., and Yu W.P. Ultrathin polyethylene-glycol-polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano-dimension RBC substitutes. Artif Cells Blood Substit Immobil Biotechnol 31 (2003) 231-248
25. Liu Z.C., and Chang T.M.S. Effects of PEG-PLA-nano artificial cells containing hemoglobin on kidney function and renal histology in rats. Artificial Cells Blood Substit Biotechnol 36 (2008) 421-430
26. Liu ZC, TMS. Chang. Long-term effects on the histology and function of livers and spleens in rats after 33% toploading of PEG-PLA-nano artificial red blood cells. Artificial Cells, Blood Substitutes & Biotechnology 2008;36:513-24.
27. Yu B.L., and Chang T.M.S. In vitro and in vivo effects of polyHb-tyrosinase on murine B16F10 melanoma. Melanoma Res 14 (2004) 481-489
28. Chang T.M.S. Enzyme artificial cells in substrate-dependent tumours and activation of prodrug. Chang TMS, editor. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Singapore: World Science Publisher; 2007 (2007) 160-194
29. Hill S., Carless P., Henry D., et al. Cochrane Database Syst Rev 2 (2006) 1-41
30. Rao S., Harrington R., Califf R., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 293 (2005) 673-674
31. Rao S.V., Jollis J.G., Harrington R.A., et al. Blood transfusion in patients with acute coronary syndrome. JAMA 292 (2004) 1555-1562